Factors released by low and high-LET irradiated fibroblasts modulate migration and invasiveness of pancreatic cancer cells.

carbon ions high-LET invasion low-LET migration pancreatic cancer tumor microenvironment

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 26 07 2022
accepted: 21 09 2022
entrez: 31 10 2022
pubmed: 1 11 2022
medline: 1 11 2022
Statut: epublish

Résumé

Radiotherapy represents a major treatment option for patients with pancreatic cancer, however, its benefits remain limited also due to the ability of cancer cells to migrate to the surrounding tissues. Low-LET ionizing radiation is well known to promote tumor cell migration and invasion, nevertheless, little data provided by studies using high-LET radiation has led to ambiguous findings. What is hypothesized to be fundamental in the modulation of migration of tumor cells exposed to ionizing radiation is the influence of the microenvironment. Therefore, the properties of cells that populate the tumor stroma cannot be ignored when studying the influence of radiation on the migratory and invasive capacity of cancer cells. This is especially important in the case of pancreatic malignancies that are characterized by an abundance of stromal cells, including cancer-associated fibroblasts, which are known to orchestrate the cross-talk with tumor cells. The current study aims to investigate whether the presence of factors released by irradiated fibroblasts affects the migratory and invasive capacity of pancreatic cancer cells exposed to different doses of photons or C-ions. AsPC-1 and AG01522 cells were irradiated with the same dose of photons or C-ions at room temperature. Through Boyden chamber assay, we tested whether factors secreted by irradiated fibroblasts may influence tumor cell migration, while the invasiveness of AsPC-1 cells was assessed using matrigel precoated inserts in which medium collected from non-irradiated (0 Gy), photon and C-ion irradiated fibroblasts, was added. Data were analyzed by Student t-test using GraphPad software. The mean ± s.d. was determined with a significance level of p<0.05. In the presence of conditioned medium collected from 1 Gy and 2 Gy photon irradiated fibroblasts, the number of migrated tumor cells increased (P<0.0360, P<0.0001) but decreased at 4 Gy dose (P<0.002). There was a trend of reduction in migration (P<0.0460, P<0.038, P<0.0024, P<0.0002), as well as a decrease in invasiveness (P<0.0525, P<0.0035, P<0.0868, P<0.0310) after exposure to 0.5 Gy, 1 Gy, 2 Gy and 4 Gy of C-ions. The presence of irradiated fibroblasts affected the invasiveness capability of pancreatic cancer cells, probably by the reciprocal release of soluble factors whose production is differently modulated after high or low-LET radiation. Understanding the effects of irradiation on the metastatic potential of pancreatic cancer cells is of utmost importance for improving the outcome and tailoring the therapeutic approach. This challenging scenario requires a continuous and multidisciplinary approach that involves clinicians together with researcher experts in oncological and radiation treatment. In the last years, including preclinical experiences in a multidisciplinary approach has proved to be a winning strategy in clinical oncological research.

Identifiants

pubmed: 36313689
doi: 10.3389/fonc.2022.1003494
pmc: PMC9597630
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1003494

Informations de copyright

Copyright © 2022 Charalampopoulou, Barcellini, Ciocca, Di Liberto, Pasi, Pullia, Orlandi and Facoetti.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Lancet Oncol. 2009 Jul;10(7):718-26
pubmed: 19573801
J Radiat Res. 2011;52(3):374-9
pubmed: 21343675
Anticancer Res. 2018 Aug;38(8):4585-4591
pubmed: 30061225
Radiat Oncol. 2013 Nov 06;8:260
pubmed: 24192264
Am J Cancer Res. 2016 Oct 01;6(10):2192-2206
pubmed: 27822411
J Radiat Res. 2013 Jul;54 Suppl 1:i113-9
pubmed: 23824114
Pancreatology. 2020 Jul;20(5):1004-1005
pubmed: 32418757
Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1212-1221
pubmed: 29907490
Crit Rev Oncol Hematol. 2014 Nov;92(2):133-42
pubmed: 24908570
BMC Cancer. 2019 Sep 14;19(1):922
pubmed: 31521134
Semin Cancer Biol. 2015 Dec;35:45-52
pubmed: 26410035
Cancer Res. 2004 May 1;64(9):3215-22
pubmed: 15126362
Sci Rep. 2020 Dec 9;10(1):21517
pubmed: 33299018
Onco Targets Ther. 2020 Dec 10;13:12705-12720
pubmed: 33335406
Breast Cancer Res. 2008;10(6):215
pubmed: 19014406
Clin Transl Radiat Oncol. 2019 Apr 25;18:128-130
pubmed: 31341988

Auteurs

Alexandra Charalampopoulou (A)

Research and Development Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.

Amelia Barcellini (A)

Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.

Mario Ciocca (M)

Medical-Physics Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.

Riccardo Di Liberto (R)

Department of Medical Physics, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Francesca Pasi (F)

Medical Oncology Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

Marco Giuseppe Pullia (MG)

Research and Development Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.

Ester Orlandi (E)

Clinical Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.

Angelica Facoetti (A)

Research and Development Department, National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy.

Classifications MeSH